JP2017535613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535613A5 JP2017535613A5 JP2017545858A JP2017545858A JP2017535613A5 JP 2017535613 A5 JP2017535613 A5 JP 2017535613A5 JP 2017545858 A JP2017545858 A JP 2017545858A JP 2017545858 A JP2017545858 A JP 2017545858A JP 2017535613 A5 JP2017535613 A5 JP 2017535613A5
- Authority
- JP
- Japan
- Prior art keywords
- sublingual
- disorder
- preparation according
- riluzole
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 7
- 229960004181 riluzole Drugs 0.000 claims 7
- 210000000214 mouth Anatomy 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 231100000862 numbness Toxicity 0.000 claims 4
- 206010031009 Oral pain Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010013142 Disinhibition Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002996 emotional effect Effects 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000005976 liver dysfunction Effects 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010219 Compulsions Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 206010018286 Gingival pain Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- 206010029897 Obsessive thoughts Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034568 Peripheral coldness Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010037180 Psychiatric symptoms Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 239000004376 Sucralose Substances 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000870 cognitive problem Toxicity 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 201000003636 hereditary ataxia Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000003989 repetitive behavior Effects 0.000 claims 1
- 208000013406 repetitive behavior Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 1
- 235000019408 sucralose Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| US62/083,094 | 2014-11-21 | ||
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139429A Division JP2021001173A (ja) | 2014-11-21 | 2020-08-20 | リルゾールの舌下製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535613A JP2017535613A (ja) | 2017-11-30 |
| JP2017535613A5 true JP2017535613A5 (https=) | 2018-11-01 |
| JP6753860B2 JP6753860B2 (ja) | 2020-09-09 |
Family
ID=55085882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545858A Active JP6753860B2 (ja) | 2014-11-21 | 2015-11-17 | リルゾールの舌下製剤 |
| JP2020139429A Pending JP2021001173A (ja) | 2014-11-21 | 2020-08-20 | リルゾールの舌下製剤 |
| JP2023015640A Pending JP2023065398A (ja) | 2014-11-21 | 2023-02-03 | リルゾールの舌下製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139429A Pending JP2021001173A (ja) | 2014-11-21 | 2020-08-20 | リルゾールの舌下製剤 |
| JP2023015640A Pending JP2023065398A (ja) | 2014-11-21 | 2023-02-03 | リルゾールの舌下製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (https=) |
| EP (3) | EP3220891B1 (https=) |
| JP (3) | JP6753860B2 (https=) |
| KR (2) | KR102580378B1 (https=) |
| CN (1) | CN107249567B (https=) |
| AU (2) | AU2015350148B2 (https=) |
| BR (1) | BR112017010423B1 (https=) |
| CA (1) | CA2967662A1 (https=) |
| CY (1) | CY1122469T1 (https=) |
| DK (1) | DK3220891T3 (https=) |
| EA (1) | EA038518B1 (https=) |
| ES (3) | ES2751300T3 (https=) |
| HR (1) | HRP20191892T8 (https=) |
| HU (1) | HUE046869T2 (https=) |
| IL (2) | IL278188B2 (https=) |
| LT (1) | LT3220891T (https=) |
| MX (1) | MX368838B (https=) |
| PH (1) | PH12017500934B1 (https=) |
| PL (1) | PL3220891T3 (https=) |
| PT (1) | PT3220891T (https=) |
| RS (1) | RS59490B1 (https=) |
| SG (1) | SG11201703896QA (https=) |
| SI (1) | SI3220891T1 (https=) |
| WO (1) | WO2016081472A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| SG11202011187QA (en) * | 2018-05-27 | 2020-12-30 | Biohaven Pharm Holding Co Ltd | Use of riluzole oral disintigrating tablets for treating diseases |
| WO2020037152A1 (en) * | 2018-08-16 | 2020-02-20 | Biohaven Therapeutics Ltd. | Use of riluzole oral disintigrating tablets for treating diseases |
| JP7716396B2 (ja) * | 2019-10-22 | 2025-07-31 | アルビナス・オペレーションズ・インコーポレイテッド | 前立腺癌を治療する方法 |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| US5631023A (en) | 1993-07-09 | 1997-05-20 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| NZ336326A (en) * | 1996-12-20 | 2001-02-23 | Nutrinova Gmbh | Method for increasing the sweetening power and enhancing the taste of a mixture of extremely powerful sweetening agents |
| AU736912B2 (en) | 1997-02-20 | 2001-08-02 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| DE69834255T2 (de) | 1997-07-25 | 2006-09-28 | Alpex Pharma S.A. | Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten |
| SK288117B6 (sk) | 1998-11-20 | 2013-09-03 | Skyepharma Canada Inc. | Rapidly dispersing solid dry therapeutic dosage form |
| AU2173400A (en) | 1998-12-09 | 2000-06-26 | Chiron Corporation | Method for administering agents to the central nervous system |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| AU2002334939A1 (en) | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
| EP1485296B1 (en) | 2002-02-13 | 2011-07-20 | Michael K. Weibel | Drug dose - form and method of manufacture |
| EP2316468A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| AU2005218625A1 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| JP2009521523A (ja) | 2005-12-27 | 2009-06-04 | ジュビラント・オルガノシス・リミテッド | 口中溶解性医薬組成物およびその製造方法 |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| CN101686942B (zh) | 2007-06-27 | 2012-09-26 | 韩美药品株式会社 | 用于快速制备用于口服的崩解剂的方法及其产品 |
| US20110183942A1 (en) * | 2008-07-15 | 2011-07-28 | University Of Medicine And Dentistry Of New Jersey | Methods and Compositions for Treating Alzheimer's Disease |
| US8485861B2 (en) | 2008-10-31 | 2013-07-16 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8788212B2 (en) | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| TR201809351T4 (tr) * | 2011-03-01 | 2018-07-23 | Pharnext | Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi. |
| US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| KR101951220B1 (ko) * | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| IN2014DN07989A (https=) * | 2012-03-01 | 2015-05-01 | Pharnext | |
| MX2017006454A (es) | 2014-11-21 | 2018-03-23 | Biohaven Pharm Holding Co Ltd | Administracion sublingual de riluzol. |
| RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
-
2015
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 ES ES21169884T patent/ES3060532T3/es active Active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535613A5 (https=) | ||
| JP2017535612A5 (https=) | ||
| ES2730088T3 (es) | Formulaciones para el tratamiento de trastornos de la boca, la garganta y las vías respiratorias | |
| NO20013859L (no) | Cyklooksygenase-2 inhibitoriske medikamenter med rask inntreden av terapeutisk virkning | |
| JP2023076465A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| JP2010522137A5 (https=) | ||
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| JP2010535805A5 (https=) | ||
| WO2010116385A3 (en) | Pharmaceutical compositions for alleviating unpleasant taste | |
| JP2010520185A5 (https=) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| AR056824A1 (es) | Tableta de neramexano con matriz de liberacion modificada | |
| CN102895472B (zh) | 一种治疗口腔溃疡的外用组合药物及其制备方法 | |
| JP2011500589A5 (https=) | ||
| CN104225246A (zh) | 一种口腔溃疡膜剂及其制备方法 | |
| ES2590209T3 (es) | Composiciones para el tratamiento de la fatiga asociada al cáncer | |
| CN103623373A (zh) | 预防晕动病的内服中药 | |
| JP2021066751A (ja) | 経口用医薬組成物 | |
| CN103100020B (zh) | 一种治疗牙痛的中药制剂 | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| CN106177761B (zh) | 一种抗抑郁的中药组方及其制品 | |
| Nogueira et al. | 44265 Oral coenzyme Q10: The new authority in skin aging. Results of a randomized, double-blind, placebo-controlled trial in elderly women | |
| CN103751499A (zh) | 一种治疗口腔溃疡的中药组合物 | |
| CN101926879B (zh) | 一种治疗牙痛的中药组合物 | |
| JP7699855B2 (ja) | シロスタゾールを含む組成物の脳血管疾患の治療薬の調製への応用 |